Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.

× No keyword cloud information.

8 in total

Review 1. Novel systemic therapy against malignant pleural mesothelioma.

Authors: Michael R Mancuso; Joel W Neal
Journal: Transl Lung Cancer Res Date: 2017-06

Review 2. Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors: Polina Shindiapina; Lapo Alinari
Journal: Ther Adv Hematol Date: 2018-03-05

Review 3. Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab.

Authors: Nathan D Gay; Craig Y Okada; Andy I Chen; Emma C Scott
Journal: Ther Adv Hematol Date: 2017-03-28

Review 4. Combining drugs and extending treatment - a PFS end point is not sufficient.

Authors: Bishal Gyawali; Vinay Prasad
Journal: Nat Rev Clin Oncol Date: 2017-05-23 Impact factor: 66.675

Review 5. Treatment of relapsed and refractory Hodgkin Lymphoma.

Authors: Bastian von Tresckow; Craig H Moskowitz
Journal: Semin Hematol Date: 2016-05-12 Impact factor: 3.851

6. Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

Authors: Eileen P Smith; Hongli Li; Jonathan W Friedberg; Louis S Constine; Lisa M Rimsza; James R Cook; Ginna G Laport; Leslie L Popplewell; Leona A Holmberg; Sonali M Smith; Michael LeBlanc; Stephen J Forman; Richard I Fisher; Patrick J Stiff
Journal: Biol Blood Marrow Transplant Date: 2017-12-28 Impact factor: 5.742

Review 7. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.

Authors: Lesley J Scott
Journal: Drugs Date: 2017-03 Impact factor: 9.546

Review 8. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.

Authors: Eva M Donato; Miguel Fernández-Zarzoso; Jose Antonio Hueso; Javier de la Rubia
Journal: Onco Targets Ther Date: 2018-08-06 Impact factor: 4.147

8 in total